Jan 2 |
Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
|
Dec 1 |
Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting
|
Nov 30 |
Why Salesforce Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
|
Nov 29 |
Why Patterson Companies Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
|
Nov 29 |
Why Workday Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
|
Nov 14 |
Avenue Therapeutics GAAP EPS of $0.06 beats by $0.32
|
Nov 13 |
Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
|
Nov 6 |
Avenue Therapeutics' US$4.5m Market Cap Fall Books Insider Losses
|
Nov 2 |
Avenue Therapeutics Announces Closing of $5.0 Million Public Offering
|
Oct 31 |
Avenue Therapeutics stock plummets on pricing of 16.6M units at $0.3006 in public offering
|